Core Laboratories (CLB) Long-Term Deferred Tax (2022 - 2026)

Core Laboratories has reported Long-Term Deferred Tax for 5 years, with the latest figure at $71.3 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 5.55% year-over-year to $71.3 million; the trailing twelve-month figure through Mar 2026 stood at $71.3 million (up 5.55% YoY), and the FY2025 full-year result was $67.4 million, down 3.21% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $71.3 million, up from $67.4 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $72.3 million in Q3 2023, with the low at $66.3 million in Q1 2024.
• Historically, Long-Term Deferred Tax has averaged $69.4 million across 5 years, with a median of $69.6 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax decreased 3.29% — and 2026, when it grew 5.55%.
• Core Laboratories' Long-Term Deferred Tax stood at $68.6 million in 2022, then gained by 0.92% to $69.2 million in 2023, then increased by 0.6% to $69.6 million in 2024, then declined by 3.21% to $67.4 million in 2025, then climbed by 5.81% to $71.3 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $71.3 million (Q1 2026), $67.4 million (Q4 2025), and $70.5 million (Q3 2025), per Business Quant data.